The WHI at 30: How One Trial Reshaped Hormone Therapy for a Generation

In May 2024, JAMA published a sweeping review of the Women's Health Initiative by JoAnn Manson, Rowan Chlebowski, and colleagues — revisiting the trial that, more than any other, defined the modern conversation around menopause and hormone therapy. The WHI enrolled 161,808 postmenopausal women between 1993 and 1998 and followed them for up to 20 years. When the first results were released in 2002, showing increased risks of heart disease, breast cancer, stroke, and blood clots with combined estrogen-progestin therapy, the fallout was immediate: hormone therapy prescriptions dropped by nearly half virtually overnight.

The 2024 review does not reverse those findings. It does, however, add critical nuance. The original trial population skewed older — women aged 50 to 79, with a mean age of 63 — and used a single formulation (oral conjugated equine estrogens plus medroxyprogesterone acetate). Subsequent analyses and long-term follow-up showed that estrogen alone did not increase breast cancer risk and that younger women closer to menopause onset had a meaningfully different risk profile than the original headlines suggested. The review confirms that hormone therapy should not be used to prevent chronic disease, but remains effective for managing moderate to severe vasomotor symptoms when started appropriately.

Why This Matters

The WHI study did not just change prescribing patterns — it changed how an entire generation of women and their doctors thought about menopause. Many women who could have benefited from hormone therapy during the critical window after menopause went untreated because of fears rooted in initial, incompletely contextualized results. The 2024 JAMA review represents the most authoritative recalibration to date. For platforms like Kairos™, this underscores the value of longitudinal symptom tracking and biomarker monitoring: the right intervention at the right time depends on knowing exactly where a woman is in her transition, what her risk factors are, and how her symptoms are trending — not on blanket assumptions inherited from a single trial design.